Enanta Pharmaceuticals Inc (ENTA)
13.15
-0.27
(-2.01%)
USD |
NASDAQ |
Apr 23, 16:00
13.15
0.00 (0.00%)
After-Hours: 18:10
Enanta Pharmaceuticals Cash from Financing (TTM): 190.48M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 190.48M |
September 30, 2023 | 198.13M |
June 30, 2023 | 201.08M |
March 31, 2023 | 5.324M |
December 31, 2022 | 10.70M |
September 30, 2022 | 20.03M |
June 30, 2022 | 18.05M |
March 31, 2022 | 14.61M |
December 31, 2021 | 12.41M |
September 30, 2021 | 3.08M |
June 30, 2021 | 2.37M |
March 31, 2021 | 4.91M |
December 31, 2020 | 8.116M |
September 30, 2020 | 8.983M |
June 30, 2020 | 9.437M |
March 31, 2020 | 6.701M |
December 31, 2019 | 2.60M |
September 30, 2019 | 2.574M |
June 30, 2019 | 2.92M |
March 31, 2019 | 5.395M |
December 31, 2018 | 5.132M |
September 30, 2018 | 4.409M |
June 30, 2018 | 4.383M |
Date | Value |
---|---|
March 31, 2018 | 1.608M |
December 31, 2017 | 1.403M |
September 30, 2017 | 1.017M |
June 30, 2017 | 0.071M |
March 31, 2017 | 1.849M |
December 31, 2016 | 2.59M |
September 30, 2016 | 2.705M |
June 30, 2016 | 2.803M |
March 31, 2016 | 0.957M |
December 31, 2015 | 0.672M |
September 30, 2015 | 2.54M |
June 30, 2015 | 2.425M |
March 31, 2015 | 2.777M |
December 31, 2014 | 3.089M |
September 30, 2014 | 1.164M |
June 30, 2014 | 1.242M |
March 31, 2014 | -0.677M |
December 31, 2013 | 58.32M |
September 30, 2013 | 56.91M |
June 30, 2013 | 55.80M |
March 31, 2013 | 57.22M |
December 31, 2012 | -2.28M |
September 30, 2012 | -0.909M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.37M
Minimum
Jun 2021
201.08M
Maximum
Jun 2023
38.03M
Average
8.983M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | 595.12M |
Galectin Therapeutics Inc | 40.03M |
Viking Therapeutics Inc | 271.38M |
Akero Therapeutics Inc | 353.32M |
89bio Inc | 513.11M |